Blesa Joan Manel Gasent, Mollá Sara Blasco, Esparcia María Fonfría, Ortells José Miguel Sempere, Godoy Miguel Peris, Das Adrian Munilla, Magan Balbino Mancheño, Pulla Mariano Provencio, Sanchez Jose Luis, Canales Juan Bautista Laforga, Candel Vicente Alberola
Department of Medical Oncology, Hospital de Dénia, Marina Salud, Dénia, Spain.
Case Rep Oncol. 2012 Sep;5(3):676-81. doi: 10.1159/000341852. Epub 2012 Dec 20.
Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are required to treat these difficult diseases. Here we present a durable complete remission of a relapsed glioblastoma that has achieved a complete radiologic response with the combination of cetuximab and bevacizumab, in a third-line setting, that has offered a progression-free survival of 20 months. We consider here both potential mechanisms for the explanation of this result. First, the potential target of the cancer stem cells (CSCs) with these two antibodies, and second, the potential recruitment of the immune system to directly pursue the CSCs.
目前，复发性胶质瘤的治疗是一项临床挑战。需要新的有效治疗方法来治疗这些难治性疾病。在此，我们报告了一例复发性胶质母细胞瘤的持久完全缓解病例，该病例在三线治疗中联合使用西妥昔单抗和贝伐单抗后取得了完全的影像学反应，无进展生存期达20个月。我们在此探讨了可能解释这一结果的两种潜在机制。第一，这两种抗体对癌症干细胞（CSCs）的潜在靶向作用；第二，免疫系统可能直接针对CSCs的募集作用。
